SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-039736
Filing Date
2024-04-02
Accepted
2024-04-02 06:04:21
Documents
15
Period of Report
2024-03-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stro-20240329.htm   iXBRL 8-K 53999
2 EX-99.1 stro-ex99_1.htm EX-99.1 41207
3 GRAPHIC img217863751_0.jpg GRAPHIC 3307
4 GRAPHIC img217863751_1.jpg GRAPHIC 4634
5 GRAPHIC img217863751_2.jpg GRAPHIC 5459
  Complete submission text file 0000950170-24-039736.txt   238142

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stro-20240329.xsd EX-101.SCH 25176
18 EXTRACTED XBRL INSTANCE DOCUMENT stro-20240329_htm.xml XML 4527
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

IRS No.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 24812110
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)